(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 March 2005 (24.03.2005)

PCT

(10) International Publication Number
WO 2005/026130 A1

(51) International Patent Classification[7]: C07D 239/48, 405/12, 403/12, 401/12, 401/14, A61K 31/506, 35/00

(21) International Application Number:
PCT/EP2004/010466

(22) International Filing Date:
17 September 2004 (17.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/504,374 18 September 2003 (18.09.2003) US

(71) Applicant *(for all designated States except AT, US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant *(for AT only)*: **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **IMBACH, Patricia** [CH/CH]; Mattenweg 7, CH-4303 Kaiseraugst (CH). **ROESEL, Johannes** [DE/CH]; Unterm Schellenberg 211, CH-4125 Riehen (CH).

(74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/026130 A1

(54) Title: 2,4-DI (PHENYLAMINO) PYRIMIDINES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS



(I)

(57) Abstract: There is provided a method of preventing or treating proliferative disorders such as a tumor disease, by inhibiting ALK activity with compounds of formula (I) wherein X, R^1, R^2, R^3, R^4, R^5, R^6, R^7,R^8 and R^9 are as indicated in claim 1.

2,4-DI(PHENYLAMINO)PYRIMIDINES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS

Use of Pyrimidine Derivatives

The present invention relates the use of pyrimidine derivatives for the treatment of proliferative disorders, such as cancer, and to pharmaceutical compositions comprising them for the treatment of such proliferative disorders.

More particularly the present invention is based on the discovery that certain pyrimidine derivatives possess valuable, pharmacologically useful properties. In particular the pyrimidine derivatives used according to the present invention exhibit specific inhibitory activities that are of pharmacological interest. They are effective especially as protein tyrosine kinase inhibitors; they exhibit, for example, powerful inhibition of the tyrosine kinase activity of anaplastic lymphoma kinase (ALK) and the fusion protein of NPM-ALK . This protein tyrosine kinase results from a gene fusion of nucleophosmin (NPM) and the anaplastic lymphoma kinase (ALK), rendering the protein tyrosine kinase activity of ALK ligand-independent. NPM-ALK plays a key role in signal transmission in a number of hematopoetic and other human cells leading to hematological and neoplastic diseases, for example in anaplastic large-cell lymphoma (ALCL) and non-Hodgkin's lymphomas (NHL), specifically in ALK+ NHL or Alkomas, in inflammatory myofibroblastic tumors (IMT) and neuroblastomas. In addition to NPM-ALK other gene fusions have been identified in human hematological and neoplastic diseases; mainly TPM3-ALK (a fusion of nonmuscle tropomyosin with ALK). The pyrimidine derivatives are useful for the inhibition of all such ALK-containing gene fusions.

The compounds that are useful as inhibitors of ALK or a gene fusion containing ALK are especially compounds of formula I



(I)

wherein

X is $=CR^0-$ or $=N-$;

each of R^0, R^1, R^2, R^3 and R^4 independently is hydrogen; hydroxy; C_1-C_8alkyl; C_2-C_8alkenyl;

C_3-C_8cycloalkyl; C_3-C_8cycloalkyl-C_1-C_8alkyl; hydroxyC_1-C_8alkyl; C_1-C_8alkoxyC_1-C_8alkyl; hydroxyC_1-C_8alkoxyC_1-C_8alkyl; arylC_1-C_8alkyl which optionally may be substituted on the ring by hydroxy, C_1-C_8alkoxy, carboxy or C_1-C_8alkoxycarbonyl;

or R^3 and R^4 form together with the nitrogen and carbon atoms to which they are attached a 5 to 10 membered heterocyclic ring and comprising additionally 1, 2 or 3 heteroatoms selected from N, O and S;

or each of R^1, R^2 and R^3, independently, is halogen; halo-C_1-C_8alkyl; C_1-C_8alkoxy; halo-C_1-C_8alkoxy; hydroxyC_1-C_8alkoxy; C_1-C_8alkoxyC_1-C_8alkoxy; aryl; arylC_1-C_8alkoxy; heteroaryl; heteroaryl-C_1-C_4alkyl; 5 to 10 membered heterocyclic ring; nitro; carboxy; C_2-C_8alkoxycarbonyl; C_2-C_8alkylcarbonyl; -N(C_1-C_8alkyl)C(O) C_1-C_8alkyl; -N(R^{10})R^{11}; -CON(R^{10})R^{11}; -SO_2N(R^{10})R^{11}; or -C_1-C_4-alkylene-SO_2N(R^{10})R^{11}; wherein each of R^{10} and R^{11} independently is hydrogen; hydroxy; C_1-C_8alkyl; C_2-C_8alkenyl; C_3-C_8cycloalkyl; C_3-C_8cycloalkyl-C_1-C_8alkyl; C_1-C_8alkoxyC_1-C_8alkyl; hydroxyC_1-C_8alkoxyC_1-C_8alkyl; hydroxyC_1-C_8alkyl; (C_1-C_8alkyl)-carbonyl; arylC_1-C_8alkyl which optionally may be substituted on the ring by hydroxy, C_1-C_8alkoxy, carboxy or C_2-C_8alkoxycarbonyl; or 5 to 10 membered heterocyclic ring;

or R^1 and R^2 form together with the C-atoms to which they are attached aryl or a 5 to 10 membered heteroaryl residue comprising one or two heteroatoms selected from N, O and S; or

each of R^5 and R^6 independently is hydrogen; halogen; cyano; C_1-C_8alkyl; halo-C_1-C_8alkyl; C_2-C_8alkenyl; C_2-C_8alkynyl; C_3-C_8cycloalkyl; C_3-C_8cycloalkylC_1-C_8alkyl; C_5-C_{10}arylC_1-C_8alkyl;

each of R^7, R^8 and R^9 is independently hydrogen; hydroxy; C_1-C_8alkyl; C_2-C_8alkenyl; halo-C_1-C_8alkyl; C_1-C_8alkoxy; C_3-C_8cycloalkyl; C_3-C_8cycloalkylC_1-C_8alkyl; arylC_1-C_8alkyl; -Y-R^{12} wherein Y is a direct bond or O and R^{12} is a substituted or unsubstituted 5, 6 or 7 membered heterocyclic ring comprising 1, 2 or 3 heteroatoms selected from N, O and S; carboxy; (C_1-C_8alkoxy)-carbonyl; -N(C_{1-8}alkyl)-CO-N$R^{10}R^{11}$; -CON$R^{10}R^{11}$; -N(R^{10})(R^{11}); -SO_2N(R^{10})R^{11}; or R^7 and R^8 or R^8 and R^9, respectively form together with the carbon atoms to which they are attached, a 5 or 6 membered heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S; or a 5 or 6 membered carbocyclic ring.

in free form or salt form.

Any aryl may be phenyl, naphthyl or 1,2,3,4-tetrahydronaphthyl, preferably phenyl. Heteroaryl is an aromatic heterocyclic ring, e.g. a 5 or 6 membered aromatic heterocyclic ring, optionally condensed to 1 or 2 benzene rings and/or to a further heterocylic ring.

Any heterocyclic ring may be saturated or unsaturated and optionally condensed to 1 or 2 benzene rings and/or to a further heterocyclic ring.

Examples of heterocyclic rings or heteroaryl include e.g. morpholinyl, piperazinyl, piperidyl, pyrrolidinyl, pyridyl, purinyl, pyrimidinyl, N-methyl-aza-cycloheptan-4-yl, indolyl, quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydroquinolinyl, benzothiazolyl, thiazolyl, imidazolyl, benzimidazolyl, benzoxadiazolyl, benzotriazolyl, indanyl, oxadiazolyl, pyrazolyl, triazolyl, and tetrazolyl. Preferred heterocyclic rings or heteroaryl are morpholinyl, piperazinyl, piperidyl, pyrrolidinyl, pyridyl, N-methyl-aza-cycloheptan-4-yl, thiazolyl, imidazolyl and tetrazolyl.

When R^7 and R^8 or R^8 and R^9 form together with the carbon atoms to which they are attached a 5 or 6 membered carbocyclic ring, this may preferably be cyclopentyl or cyclohexyl.

Halo-alkyl is alkyl wherein one or more H are replaced by halogen, e.g. CF_3.

Any alkyl or alkyl moiety may be linear or branched. C_{1-8}alkyl is preferably C_{1-4}alkyl. C_{1-8}alkoxy is preferably C_{1-4}alkoxy. Any alkyl, alkoxy, alkenyl, cycloalkyl, heterocyclic ring, aryl or heteroaryl may be, unless otherwise stated, unsubstituted or substituted by one or more substituents selected from halogen; OH; C_1-C_8alkyl; C_1-C_8alkoxy; nitro; cyano; COOH; carbamoyl; $C(NH_2)$=NOH; $-N(R^{10})R^{11}$; C_3-C_6cycloalkyl; 3 to 7 membered heterocyclic ring; phenyl; phenyl-C_{1-4}alkyl; 5 or 6 membered heteroaryl. When alkyl, alkoxy or alkenyl is substituted, the substituent is preferably on the terminal C atom. When the heterocyclic ring or heteroaryl is substituted, e.g. as disclosed above, this may be on one or more ring carbon atoms and/or ring nitrogen atom when present. Examples of a substituent on a ring nitrogen atom are e.g.
C_{1-8}alkyl, carbamoyl, $-C(NH_2)$=NOH, $-NR^{10}R^{11}$, C_{3-6}cycloalkyl or phenyl-C_{1-4}alkyl, preferably C_{1-8}alkyl, C_{3-6}cycloalkyl or phenyl-C_{1-4}alkyl.

Preferably substituted alkyl or alkoxy as R_7 is alkyl or alkoxy substituted on the terminal C atom by OH, C_{1-4}alkoxy or a heterocyclic ring. When R^{10} or R^{11} is a 5 to 10 membered heterocyclic ring, it may be e.g. thiazolyl.

Halogen may be F, Cl, Br, or I.

Preferably at most one of R^1, R^2 or R^3 is $CONR^{10}R^{11}$ or $SO_2NR^{10}R^{11}$, more preferably $SO_2NR^{10}R^{11}$.

The compounds of the invention may exist in free form or in salt form, e.g. addition salts with e.g. organic or inorganic acids, for example trifluoroacetic acid or hydrochloride acid, or salts obtainable when they comprise a carboxy group, e.g. with a base, for example alkali salts such as sodium, potassium, or substituted or unsubstituted ammonium salts.

In formula I the following significances are preferred independently, collectively or in any combination or sub-combination:

(a) X is $=CR^0$;

(b) R^0 is hydrogen; halogen, e.g. Cl; C_1-C_4alkyl, e.g. methyl or ethyl; C_{1-4}alkoxy, e.g. methoxy; preferably hydrogen;

(c) R^1 is hydrogen; halogen, e.g. Cl or F; OH; C_1-C_8alkyl, e.g. methyl or ethyl; substituted C_{1-8}alkyl, e.g. terminally OH substituted C_{1-8}alkyl; $-SO_2N(R^{10})R^{11}$; $-N(C_{1-4}alkyl)C(O)$ C_{1-4}alkyl; a 5 or 6 membered heterocyclic ring optionally substituted on a ring N atom (when possible); C_1-C_8alkoxy, e.g. methoxy; aryl, e.g. phenyl; or form together with R^2 and the C-atoms to which R^1 and R^2 are attached 5 to 10 membered aryl or heteroaryl, the latter comprising 1 or 2 nitrogen atoms;

(d) R^2 is hydrogen; hydroxy; C_1-C_8alkyl, e.g. methyl or ethyl; substituted C_{1-8}alkyl, e.g. terminally OH- or C_{1-4}-alkoxy substituted C_{1-8}alkyl; C_{1-8}alkoxy; C_1-C_4alkoxyC_1-C_8alkoxy; $-CON(R^{10})R^{11}$;
$-SO_2N(R^{10})R^{11}$; or forms together with R^1 and the C-atoms to which R^1 and R^2 are attached a 5 to 10 membered aryl or heteroaryl, the latter comprising 1 or 2 nitrogen atoms;

(e) R^3 is hydrogen; halogen, e.g. Cl, Br; hydroxy; C_1-C_8alkyl, e.g. methyl or ethyl; substituted C_{1-8}alkyl, e.g. terminally OH substituted C_{1-8}alkyl; carboxy; $CONR^{10}R^{11}$; $-SO_2N(R^{10})R^{11}$; a 5 or 6 membered heterocyclic ring optionally substituted on a ring nitrogen atom (when possible); or forms together with R^4 and the N and C atoms to which R^3 and R^4 are attached a 6 membered heterocyclic ring;

(f) R^4 is hydrogen; or forms together with R^3 and the N and C atoms to which R^3 and R^4 are attached a 6 membered heterocyclic ring; preferably hydrogen;

(g) R^5 is hydrogen; halogen; C_{1-4}alkyl; or CF_3;

(h) R^6 is hydrogen;

(i) R^7 is hydrogen; hydroxy; C_{1-4}alkyl; substituted C_{1-4}alkyl, e.g. terminally OH substituted C_{1-4}alkyl; C_{1-8}alkoxy; substituted C_{1-8}alkoxy, e.g. terminally substituted by OH, C_{1-4}alkoxy or a heterocyclic ring; $NR^{10}R^{11}$; $-SO_2N(R^{10})R^{11}$; $-Y-R^{12}$; CF_3; or R^7 forms together with R^8 and the C-atoms to which R^7 and R^8 are attached a 5 membered heteroaryl residue, e.g. bridged by -NH-CH=CH-, -CH=CH-NH-, -NH-N=CH-, -CH=N-NH-, -NH-N=N- or -N=N-NH-;

(k) R^8 is hydrogen; hydroxy; C_{1-4}alkoxy; carboxy; a 5 or 6 membered heterocyclic ring optionally substituted on a ring C or N atom; $N(C_{1-4}alkyl)$-CO- $NR^{10}R^{11}$; or forms with R^7 or R^9 and the C-atoms to which R^7 and R^8 or R^8 and R^9 , respectively, are attached a 5 membered heteroaryl residue, e.g. bridged by –NH-CH=CH-, -CH=CH-NH-, –NH-N=CH-, –CH=N-NH-, –NH-N=N- or –N=N-NH-;

(l) R^9 is hydrogen; C_{1-4}alkoxy; $NR^{10}R^{11}$; or forms with R^8 and the C atoms to which R^8 and R^9 are attached a 5 membered heteroaryl, e.g. bridged by –NH-CH=CH-, -CH=CH-NH-, –NH-N=CH-, –CH=N-NH-, –NH-N=N- or –N=N-NH-;

(m) one of R^{10} and R^{11}, independently, is hydrogen or C_{1-4}alkyl and the other is hydrogen; OH; C_{1-8}alkyl, substituted C_{1-8}alkyl, e.g. terminally substituted by OH, C_{3-6}cycloalkyl or a heterocyclic ring; C_{2-8}alkenyl; C_{3-8}cycloalkyl; hydroxyC_{1-8}alkoxyC_{1-8}alkyl; or a 5 membered heterocyclic ring.

R^3 is preferably $SO_2NR^{10}R^{11}$.

The invention also provides the use of a compound of formula I for the preparation of a medicament for the treatment of a hematological and neoplastic disease.

The present invention also provides a process for the production of a compound of formula I, comprising reacting a compound of formula II



(II)

wherein R^1, R^2, R^3, R^4, R^5, R^6 and X are as defined above, and Y is a leaving group, preferably halogen such as bromide, iodine, or in particular chloride;

with a compound of formula III



(III)

wherein R^7, R^8 and R^9 are as defined above;

and recovering the resulting compound of formula I in free or in form of a salt, and, where required, converting the compound of formula I obtained in free form into the desired salt form, or vice versa.

The process may be performed according to methods known in the art, e.g. as described in examples 1 to 4.

The compound of formula II used as starting materials may be obtained by reacting a compound of formula IV



(IV)

with a compound of formula V



(V)

wherein R^1, R^2, R^3, R^4, R^5, R^6, Y and X are as defined above.

The compounds of formula IV and V are known or may be produced in accordance with known procedures.

The following examples illustrate the invention without any limitation.

The following abbreviations are employed: APC = allophycocyanine, BINAP = 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, cDNA = complementary DNA, DCM = dichloromethane, DIAD = diisopropyl azodicarboxylate, DMAP = 4-dimethylaminopyridine, DMF = dimethylformamide, DMSO = dimethylsulfoxide, DMF = dimethylformamide; Pmc = 2,2,5,7,8-pentamethylchroman; tBu = *tert.*-butyl; DIPCDI = N,N'-diisopropylcarbodiimid; DTT = 1,4-dithio-D,L-treitol, DNA = deoxyribonucleic acid, EDTA = ethylenediaminetetra-acetic acid, Lck = lymphoid T-cell protein tyrosine kinase, LAT-11 = linker for activation of T cell , RT = room temperature; RT-PCR = reverse transcription polymerase chain reaction, MS = molecular ion (e.g. $M+H^{1+}$) determined by electrospray mass spectroscopy; Eu = europium.

Example 1: 2-[2-(1H-Indazol-6-ylamino)-pyrimidin-4-ylamino]-benzenesulfonamide



(a) 2-(2-Chloro-pyrimidin-4-ylamino)-benzenesulfonamide: To a suspension of 8.52 g (49.47 mmol) 2-aminobenzenesulfonamide in 200 ml isopropanol is added 22.1 g (148.42 mmol, 3 equivalent) 2,4-dichloropyrimidine and 20 ml 10 M hydrochloric acid (200 mmol, 4 equivalent). The suspension is stirred at 60°C for 2 h 15 min. The reaction mixture is dilluted with 2 l ethyl acetate and 500 ml water is added. The pH is adjusted to 8-9 by addition of sodium bicarbonate. The layers are separated and the aqueous layer is reextracted with 500 ml ethyl acetate. The organic layers are dried with sodium sulfate, filtered and evaporated to a volume of 300 ml. A crystalline precipitate is formed and removed by filtration (side product). The filtrate is evaporated to 100 ml whereupon the product crystallizes to give 2-(2-chloro-pyrimidin-4-ylamino)-benzenesulfonamide (97% purity by HPLC). The mother liquor of this cristallisation is further purified by column chromatography and crystallisation to give further 2-(2-chloro-pyrimidin-4-ylamino)-benzenesulfonamide.

(b) 2-[2-(1H-Indazol-6-ylamino)-pyrimidin-4-ylamino]-benzenesulfonamide: To a suspension of 7.25 g (25.46 mmol) 2-(2-Chloro-pyrimidin-4-ylamino)-benzenesulfonamide and 4.07 g (30.55 mmol, 1.2 equivalent) 6-aminoindazole in 400 ml isopropanol is added 13 ml conc. HCl* (130 mmol, 5 equivalent). The suspension is refluxed for 4 h 30 min. The reaction mixture is dilluted with 1.5 l ethyl acetate and 1 l water is added. The pH is adjusted to 8-9 by addition of sodium bicarbonate. The layers are separated and the aqueous layer is re-extracted with 500 ml ethyl acetate. The organic layers are dried with sodium sulfate, filtered and evaporated to a volume of 300 ml. A crystalline precipitate (1.01 g) is formed and removed by filtration (side product). The filtrate is purified by chromatography on 200 g silica gel eluting with ethyl acetate/methanol 95/5 v/v. Upon evaporation crystalls are formed which are filtered to give the title compound.

^{1}H NMR (400 MHz, DMSO-d_6): □ 9.42 (s, 1H), 8.34 (d, 1h), 8.28 (d, 1H), 8.27 (s, 1H), 7.93 (s, 1H, 7.88 (d, 1H), 7.62 (m, 2H), 7.32 (d, 1H), 7.24 (t, 1H), 6.40 (d, 1H).

MS *m/z* (%): 382 (M+H, 100);

Example 2: 2-[2-(3,4,5-Trimethoxy-phenylamino)-pyrimidin-4-ylamino]-benzenesulfonamide



The title compound is prepared from 2-(2-chloro-pyrimidin-4-ylamino)-benzenesulfonamide as described in Example 1 using 3,4,5-Trimethoxy-phenylamine instead of 6-aminoindazole in step (b).

^{1}H NMR (400 MHz, DMSO-d_6): □ 9.18 (s, 1H), 8.22 (d, 1H), 8.17 (d, 1H), 7.89 (d, 1H), 7.55 (t, 1H), 7.25 (t, 1H), 7.14 (s, 2H), 6.40 (d, 1H), 3.69 (s, 6H), 3.62 (s, 3H). MS *m/z* (%): 432 (M+H, 100);

Example 3: 2-methyl-6-[2-(3,4,5-Trimethoxy-phenylamino)-pyrimidin-4-ylamino]-benzenesulfonamide



The tilte compound is prepared as described in Example 1 with the difference that in step (a) 2-amino-6-methyl-benzenesulfonamide is used instead of 2-aminobenzenesulfonamide.

2-Amino-6-methyl-benzenesulfonamide may be prepared as described by Girard, Y el al.; J. J. Chem. Soc. Perkin Trans. I ***1979****, 4, 1043-1047:* Under an atmosphere of nitrogen m-toluidin (32.1 g, 32.5 ml, 0.30 mmol) is added dropwise to a solution of chlorosulfonyl isocyanate (51.3 ml, 83.6 g, 0.59 mmol) in nitroethane (400 ml) at –55 – 49°C. The cold bath is removed and the mixture allowed to warm to –8°C, whereupon aluminium chloride (51 g, 0.38 mmol) is added. Heating the mixture to 100°C for 20 min forms a clear brown solution, which is cooled to RT and poured on ice. After filtration, washing with ice water and diethyl ether the precipitate is collected and dissolved in dioxane (300 ml). Water (1000 ml) and conc. HCl (1500 ml) are added to form a suspension, which is heated to 120°C for 18h. After cooling to RT the clear brown solution is washed with diethyl ether/hexane (1400 ml, 1/1 v/v) and adjusted to pH = 8 by addition of sodium carbonate. Extraction using ethyl acetate (2 x 1000 ml), washing of the organic phase with water (500 ml) and brine (500 ml), drying

(magnesium sulfate) and concentration yields a brown solid, which is purified by chromatography on silica using methylene chloride/ethanol (100/1 v/v) to yield the desired product as a white solid.

Melting point: 72-75°C (Propan-2-ol);

^{1}H NMR (400 MHz, DMSO-d_6): □ 2.64 (s, 3H, Me), 3.63 (s, 3H, OMe), 3.68 (s, 6H, OMe), 6.31 (d, J = 5Hz, 1H, pyrimidine CH), 7.07 (d, J = 8Hz, 1H, arom. CH), 7.15 (s, 2H, arom. CH), 7.40 (t, J = 8Hz, 1H, arom. CH), 7.65 (s, 2H, SO_2NH_2), 8.04 (d, J = 8Hz, 1H, arom. CH), 8.12 (d, J = 5Hz, 1H, pyrimidine CH), 9.14 (s, 1H, NH), 9.40 (s, 1H, NH).

MS (ES^+) *m/z*: 446 (MH^+), 468 (MNa^+)

MS (ES^-): 444 $(M-H)^-$

Example 4: 2-Methoxy-6-[2-(3,4,5-trimethoxy-phenylamino)-pyrimidin-4-ylamino]-benzenesulfonamide



The title compound is prepared as described in Example 1 with the difference that in step (a) 2-amino-6-methoxy-benzenesulfonamide is used instead of 2-Amino-6-methyl-benzenesulfonamide.

2-Amino-6-methoxy-benzenesulfonamide may be prepared from 12.3 g of *meta*-anisidine following an analogous procedure as described in Example 1a. NMR (400 MHz, DMSO-d_6): □3.62 (s, 3H, OMe), 3.69 (s, 6H, OMe), 3.91 (s, 3H, OMe), 6.31 (d, J = 5Hz, 1H, pyrimidine CH), 6.86 (d, J = 8Hz, 1H, arom. CH), 7.12 (s, 2H, arom. CH), 7.43 (t, J = 8Hz, 1H, arom. CH), 8.01 (d, J = 8Hz, 1H, arom. CH), 8.11 (d, J = 5Hz, 1H, pyrimidine CH), 9.18 (s, 1H, NH), 9.79 (br, 1H, NH).

MS (ES^+): 462.2 (MH^+), 484.2 (MNa^+)

MS (ES^-): 460.3 $(M-H)^-$

The compounds of formula X_1



wherein R^3, R^7 and R^8 are as defined in Table 1, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.

TABLE 1

Example	R^3	R^7	R^8	MS Data		
				*ES+	*ES-	*EI
5	-OH	-O-(1-methyl)-azacycloheptyl-4-yl	-H	406	404	
6	$-SO_2NH_2$	-O-(1-methyl)-azacycloheptyl-4-yl	-H	469.3		
7	$-SO_2NH_2$	-O-2-(1-methyl-azacyclopentyl-2-yl)-ethyl	-H	469.3		
8	-OH	-O-2-(1-piperidyl)-ethyl	$-OCH_3$	436.3	434.4	
9	-OH	-O-2-(1-methyl-azacyclopentyl-2-yl)-ethyl	-H	406	404	
10	$-SO_2NH_2$	$-O-CH_2CH_2CH_2$-1-imidazolyl	$-OCH_3$	496	494	
11	$-SO_2NH_2$	-O-2-(1-piperidyl)-ethyl	$-OCH_3$	499.2	497.3	
12	$-SO_2NH_2$	$-O-CH_2CH_2$-1-methyl-imidazol-1-yl	-H	466	464	
13	-OH	-O-2-[1-(1,2,4-triazolyl)]-ethyl	-H	390	388	
14	-OH	-O-2-hydroxyethyl	$-OCH_3$	369.4	367.3	
15	$-SO_2NH_2$	-O-2-hydroxyethyl	$-OCH_3$			431
16	$-SO_2NH_2$	$-O-CH_2CH_2$-1-imidazolyl	$-OCH_3$			
17	$-SO_2NH_2$	-O-2-[1-(1,2,4-triazolyl)]-ethyl	-H			452
18	$-SO_2NH_2$	-NH-N=N-			381	
19	$-SO_2NHCH_3$	$-O-CH_2CH_2$-1-imidazolyl	$-OCH_3$	496	494	
20	$-SO_2NH_2$	-O-2-(1-piperidyl)-ethyl	-H	469	467	
21	$-SO_2NH_2$	$-O-CH_2CH_2$-1-imidazolyl	-H	452	450	
22	-OH	-O-2-(1-piperidyl)-ethyl	-H	406		
23	-COOH	-4-morpholino	-H			
24	-OH	$-O-CH_2CH_2CH_2$-1-imidazolyl	$-OCH_3$	433	431	
25	$-SO_2NHCH_3$	-CH=N-NH-		396	394	
26	$-SO_2NH_2$	-O-2-(4-morpholino)ethyl	-H	471	469	
27	$-SO_2NH_2$	$-OCH_3$	$-OCH_3$	402	400	
28	-OH	-O-2-(4-morpholino)ethyl	-H	408	406	
29	$-SO_2NH_2$	-CH=N-NH-				381
30	$-SO_2NHCH_3$	$-O-CH_2CH_2$-1-imidazolyl	-H			

31	-COOH	Amino	-H	322		
32	$-SO_2NH_2$	$-O-CH_2CH_2CH_2$-1-imidazolyl	-H	466.2	464.3	
33	-COOH	$-N(CH_3)_2$	-H			
34	-5-(1,2,3,4-tetrazolyl)	$-NH-C(O)CH_3$	-H	388	386	
35	$-SO_2NHCH_3$	-NH-N=CH-				
36	-COOH	-OH	-H			
37	-COOH	-H	-4-piperidyl			
38	-COOH	$-CH_2$-OH	-H			
39	-OH	$-O-CH_2CH_2$-1-imidazolyl	-OCH3			
40	$-SO_2NH-CH_2CH_2-OH$	$-O-CH_2CH_2$-1-imidazolyl	-H	496	494	
41	$-C(O)NH_2$	Amino	-H	321		
42	$-SO_2NH_2$	-CH=CH-NH-		381		
43	-5-(1,2,3,4-tetrazolyl)	$-NHCH_2$-3-pyridyl	-H		435	
44	$-SO_2NH_2$	-NH-CH=CH-			379	
45	-COOH	-H	-4-morpholino			
46	-COOH	-H	-1-(4-amino)-piperidyl			
47	$-SO_2NH_2$	$-OCH_3$	-H	372	370	
48	$-SO_2N(CH_3)_2$	$-O-CH_2CH_2$-1-imidazolyl	-H	480	478	

The compounds of formula X_2



wherein R^3 and R^8 are as defined in Table 2, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.

TABLE 2

Example	R^3	R^8	MS Data	
			*ES+	*ES-
49	-COOH	$-OCH_3$	397	395
50	$-SO_2NH_2$	-OH		
51	$-SO_2NHCH_3$	$-OCH_3$		
52	-5-(1,2,3,4-tetrazolyl)	$-OCH_3$	421	
53	$-SO_2NH$-cyclopropyl	$-OCH_3$	472.2	470.3
54	-C(O)NHOH	$-OCH_3$	412	410
55	$-SO_2NH-CH_2CH_2-OH$	$-OCH_3$	476	474
56	$-SO_2N(CH_3)_2$	$-OCH_3$	460.3	458.3
57	-OH	$-OCH_3$	369	367
58	$-SO_2NH-CH_2CH_2CH_3$	$-OCH_3$	474	472
59	$-CH_2OH$	$-OCH_3$		
60	$-SO_2NH_2$	-H	402	

The compounds of formula X_3



wherein R^1, R^7, R^8 and R^9 are as defined in Table 3, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.

TABLE 3

Example	R^1	R^7	R^8	R^9	MS Data	
					*ES+	*ES-
61	$-SO_2NH-CH_2CH_2-O-CH_2CH_2-OH$	-H	$-N(CH_3)-C(O)CH_3$	-H		
62	$-SO_2NH_2$	$-OCH_3$	$-OCH_3$	$-OCH_3$		
63	$-SO_2NH_2$	$-O-CH_2CH_2$-1-imidazolyl	$-OCH_3$	-H		
64	$-SO_2NH-CH_2CH_2-O-CH_2CH_2-OH$	$-OCH_3$	$-OCH_3$	$-OCH_3$	520	518
65	$-N(CH_3)$ C(O)CH_3	$-OCH_3$	$-OCH_3$	$-OCH_3$	424	422
66	$-CH_2CH_2-OH$	$-SO_2NH-$	-H	-H		

		$CH_2CH_2CH_2CH_3$				
67	$-SO_2NH_2$	$-OCH_3$	-H	$-OCH_3$		
68	$-SO_2NH_2$	$-O-CH_2CH_2$-1-imidazolyl	-H	-H		
69	$-CH_2CH_2-OH$	$-O-CH_2CH_2$-1-imidazolyl	-H	-H		
70	$-CH_2CH_2-OH$	$-OCH_3$	-H	$-OCH_3$		
71	$-SO_2NH_2$	-OH	-H	-H		
72	$-O-CH_2CH_2-OH$	$-O-CH_2CH_2$-1-imidazolyl	-H	-H		
73	$-SO_2NH$-2-thiazolyl	$-OCH_3$	$-OCH_3$	$-OCH_3$	515	513

The compounds of formula X_4



wherein R^2, R^5, R^7, R^8 and R^9 are as defined in Table 4, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.

TABLE 4

Example	**R^2**	**R^5**	**R^7**	**R^8**	**R^9**	MS Data	
						*ES+	*ES-
74	$-SO_2NH$-2-propenyl	-H	$-OCH_3$	$-OCH_3$	$-OCH_3$	472	470
75	$-SO_2NH_2$	-H	$-OCH_3$	$-OCH_3$	$-OCH_3$		
76	-OH	-H	-O-(1-methyl)-azacyclohept-4-yl	-H	-H	406.3	404.3
77	-OH	-H	$-O-CH_2CH_2-OH$	$-OCH_3$	-H	369	367
78	$-SO_2NH_2$	-Br	$-OCH_3$	$-OCH_3$	$-OCH_3$	510.1/ 512.1	508.1/ 510.2
79	$-SO_2NH_2$	-H	-CH=N-NH-		-H	382	
80	$-SO_2NH_2$	$-CH_3$	$-OCH_3$	$-OCH_3$	$-OCH_3$	446	444
81	$-SO_2NH_2$	-H	$-O-CH_2CH_2$-1-imidazolyl	$-OCH_3$	-H	482	480
82	-OH	-H	$-O-CH_2CH_2$-1-piperidyl	$-OCH_3$	-H	436.3	434.3
83	-OH	-H	$-O-CH_2CH_2$-1-imidazolyl	$-OCH_3$	-H	419	417
84	$-SO_2NH_2$	-H	$-O-CH_2CH_2$-1-imidazolyl	-H	-H	452	450
85	$-CH_3$	-C≡N	$-OCH_3$	$-OCH_3$	$-OCH_3$	392	
86	$-SO_2NH_2$	-H	-NH-N=CH-		-H	382	

87	-OH	-H	$-OCH_3$	$-OCH_3$	$-OCH_3$	369	367
88	$-SO_2NHCH_3$	$-CH_3$	$-OCH_3$	$-OCH_3$	$-OCH_3$	460	458
89	-OH	-H	-OH	COOH	$-OCH_3$		
90	-OH	-H	$-O-CH_2CH_2$-1-piperidyl	-H	-H	406	404
91	$-SO_2NH$-2-propenyl	-H	$-O-CH_2CH_2$-1-imidazolyl	-H	-H	492.3	490.3
92	$-SO_2NH_2$	-Br	$-O-CH_2CH_2$-1-(1-methyl)-imidazolyl	-H	-H	544.1/ 546	542/ 544.2
93	$-SO_2NH_2$	-H	$-O-CH_2CH_2-OH$	$-OCH_3$	-H		
94	-OH	-H	-O-(1-methyl)-azacyclopent-2-yl	-H	-H		
95	-OH	-H	$-O-CH_2CH_2$-1-imidazolyl	-H	-H	389	387
96	-OH	-H	$-O-CH_2CH_2CH_2$-1-imidazolyl	$-OCH_3$	-H	433.4	431.4
97	$-SO_2NH_2$	-H	$-OCH_3$	-H	$-OCH_3$		
98	-OH	-H	$-OCH_3$	$-OCH_3$	-H	339	337
99	$-SO_2NHCH_2-CH_2CH_2CH_3$	-H	$-OCH_3$	$-OCH_3$	$-OCH_3$	488	486
100	$-SO_2NH-CH_3$	$-CH_3$	$-O-CH_2CH_2$-1-imidazolyl	$-OCH_3$	-H	510	508
101	$-SO_2NHCH_2-CH_2CH_2CH_3$	-H	$-O-CH_2CH_2$-1-imidazolyl	-H	-H	08	506
102	-OH	-H	$-O-CH_2CH_2$-4-morpholino	-H	-H	408	
103	-OH	-H	-NH-N=CH-		-H	319	317
104	-OH	-H	-CHN-NH-		-H	319	317
105	-OH	-H	$-O-CH_2CH_2$-1-imidazolyl	-H	-H		
106	$-SO_2NH-CH_3$	$-CH_2-CH_3$	$-OCH_3$	$-OCH_3$	$-OCH_3$	474.3	472.3
107	$-SO_2NH_2$	-H	$-OCH_3$	$-OCH_3$	$-OCH_3$		

The compounds of formula X_5



wherein R^0, R^1, R^2, R^3 and R^4 are as defined in Table 5, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.

TABLE 5

Example	R^0	R^1	R^2	R^3	R^4	MS Data	
						*ES+	*ES-
108	-H	$-OCH_3$	-OH	-H	-H		
109	-H	nitro	-H	-OH	-H	414	412
110	-H	-N=CH-CH=CH-		-H	-H		
111	-H	-CH=N-NH-		-H	-H	393	391
112	-H	-NH-N=CH-		-H	-H	393	
113	-H	-H	-OH	$-CH_2CH_2CH_2-$		409	407
114	$-CH_3$	-H	$-CH_3$	-OH	-H	397	
115	-H	phenyl	-H	$-SO_2NH_2$	-H	508	506
116	$-CH_3$	-H	-H	$-SO_2NH_2$	-H	446	444

The compounds of formula X_6



wherein R^5, R^7, R^8 and R^9 are as defined in Table 6, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.

TABLE 6

Example	R^5	R^7	R^8	R^9	*ES+	*ES-
117	$-CH_3$	$-O-CH_2CH_2$-1-imidazolyl	-H	-H	466	
118	$-CH_2CH_3$	$-OCH_3$	$-OCH_3$	$-OCH_3$	460	458
119	-Br	-NH-N=CH-		-H	461	
120	$-CH_3$	$-O-CH_2CH_2$-1-imidazolyl	$-OCH_3$	-H	496	
121	$-CH_3$	$-OCH_3$	$-OCH_3$	$-OCH_3$	446	

122	$-CH_3$	-N=N-NH-		-H	397.2	395.2
123	$-CH_3$	$-O-CH_2CH_2$-1-methyl-imidazol-1-yl	-H	-H	480	
124	-Br	-CH=N-NH-		-H	461.3	458.1/460
125	$-CH_3$	-NH-N=CH-		-H	396	
126	-Br	$-OCH_2CH_2$-(4-methyl-piperazin-1-yl)	-H	-H	562/564	560/562

The compounds of formula X_7



wherein R^1, R^2, R^3, R^7 and R^8 are as defined in Table 7, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.

TABLE 7

Ex	R^1	R^2	R^3	R^7	R^8	*ES+	*ES-
127	$-OCH_3$	-OH	-H	-OH	$-OCH_3$		
128	-H	$-CH_3$	$-SO_2NH_2$	$-O-CH_2CH_2$-1-imidazolyl	-H	466	464
129	$-OCH_3$	-OH	-H	$-O-CH_2CH_2$-1-imidazolyl	$-OCH_3$		
130	$-OCH_3$	-OH	-H	$-O-CH_2CH_2$-OH	$-OCH_3$	399	397
131	$-OCH_3$	-OH	-H	-O-(1-methyl-azacycloheptan-4-yl)	-H	436	
132	$-CH_3$	-H	$-SO_2NH_2$	$-O-CH_2CH_2$-1-imidazolyl	-H	466	464
133	$-OCH_3$	-OH	-H	$-O-CH_2CH_2$-(1-methyl)-azacyclopent-2-yl	-H	436	434
134	$-OCH_3$	-OH	-H	$-CF_3$	-H		
135	-N=CH-CH=CH-		-H	$-O-CH_2CH_2$-1-imidazolyl	$-OCH_3$		
136	$-OCH_3$	-OH	-H	$-O-CH_2CH_2CH_2$-1-imidazolyl	$-OCH_3$	463	461
137	$-OCH_3$	-OH	-H	$-O-CH_2CH_2$-1-piperidyl	$-OCH_3$	466.4	464.4
138	-CH=N-NH-		-H	-NH-N=CH-			
139	-CH=N-NH-		-H	-CH-N=NH-			

140	$-OCH_3$	-OH	-H	$-O-CH_2CH_2$-1-piperidyl	-H	436	434
141	-H	$-OCH_3$	$-SO_2NH_2$	$-O-CH_2CH_2$-1-pyrrolidinyl	-H	485.3	483.3
142	-H	$-OCH_3$	$-SO_2NH_2$	$-O-CH_2CH_2$-1-pyrrolidinyl	$-CH_3$	499.2	497.3
143	-H	$-OCH_3$	$-SO_2NH_2$	$-O-CH_2CH_2CH_2$-morpholino	$-OCH_3$	545.2	545.3
144	-H	$-OCH(CH_3)_2$	$-SO_2NH_2$	$-O-CH_2CH_2$-(4-methyl-piperazin-1-yl)	$-OCH_3$	572.2	570.3
145	-H	$-OCH_3$	$-SO_2NH_2$	$-O-CH_2CH_2$-1-piperidinyl	-H	499.2	497.3
146	$-CH_3$	$-OCH_3$	$-SO_2NH_2$	$-O-CH_2CH_2CH_2$-1-pyrrolidinyl	$-OCH_3$	543.2	
147	$-CH_3$	$-OCH_3$	$-SO_2NH_2$	$-O-CH_2CH_2CH_2$-1-pyrrolidinyl	-H	513.2	511.2
148	-H	$-OCH(CH_3)_2$	$-SO_2NH_2$	$-O-CH_2CH_2$-1-piperidinyl	-H	527.2	525.3
149	-H	$-CH_3$	$-SO_2NH_2$	$-N(CH_3)_2$	$-OCH_3$	429.3	427.3
150	$-CH_3$	$-CH_3$	$-SO_2NH_2$	$-O-CH_2CH_2CH_2$-1-pyrrolidinyl	$-OCH_3$	527.2	525.3
151	$-OCH_3$	-H	$-SO_2NH_2$	$-O-CH_2CH_2CH_2$-1-pyrrolidinyl	$-OCH_3$	529.2	527.3
152	-H	-F	$-SO_2NH_2$	$-N(CH_3)_2$	$-OCH_3$	433.1	
153	-H	$-CH_3$	$-SO_2NH_2$	$-O-CH_2CH_2$-(1-methyl-pyrrolidin-2-yl)	-H		
154	-H	$-OCH_3$	$-SO_2NH_2$	$-O-CH_2CH_2$-OH	-H	432.2	430.2
155	-H	$-CH_3$	$-SO_2NH_2$	$-O-CH_2CH_2$-(1-methyl-pyrrolidin-2-yl)	$-OCH_3$	513.2	511.3
156	$-OCH_3$	-H	$-SO_2NH_2$	$-O-CH_2CH_2$-1-piperidinyl	-H	499.2	497.3
157	$-OCH_3$	-H	$-SO_2NH_2$	$-O-CH_2CH_2$-1-pyrrolidinyl	$-OCH_3$	515.2	513.2
158	-H	$-CH_3$	$-SO_2NH_2$	$-O-CH_2CH_2$-OH	$-OCH_3$	446.2	444.2
159	$-OC_2H_5$	-H	$-SO_2NH_2$	$-O-CH_2CH_2$-1-pyrrolidinyl	$-CH_3$	513.3	511.3
160	$-OCH_3$	$-OCH_3$	$-SO_2NH_2$	$-O-CH_2CH_2$-(4-methyl-piperazin-1-yl)	$-OCH_3$	574.2	572.2
161	-H	-Cl	$-SO_2NH_2$	-(4-methyl-piperazin-1-yl)	-H	474.5	472.5
162	-H	$-CH_3$	$-SO_2NH_2$	$-O-CH_2CH_2$-(4-cyclopentyl-piperazin-1-yl)	-H	552.3	550.3
163	-CH=CH-CH=CH-		$-SO_2NH_2$	-(4-methyl-piperazin-1-yl)	-H	490.5	488.4
164	-H	-H	$-SO_2NH_2$	$-O-CH_2CH_2$-piperazin-1-yl	-H	470.2	468.3
165	-H	$-OCH_3$	-	-H	-	402.2	400.2

			SO_2NH_2		OCH_3		
166	-H	$-OCH_3$	- SO_2NH_2	-O-CH_2CH_2-(4-benzyl-piperazin-1-yl)	-H	590.3	588.3
167	$-CH_3$	-H	- SO_2NH_2	-O-CH_2CH_2-1-pyrrolidinyl	-H	469.2	467.3
168	-Br	-H	- SO_2NH_2	-O-CH_2CH_2-1-piperidinyl	-H	549.1	547.2

The compounds of formula X_8



wherein R^1, R^2, R^3 and R^8 are as defined in Table 8, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.

TABLE 8

Ex	R^1	R^2	R^3	R^8	*ES+	*ES-
169	4-morpholino	-H	-H	-H		
170	-CH=N-NH-		-H	-H	363	361
171	$-OCH_3$	-OH	-H	-H		
172	$-CH_3$	-H	$-SO_2NH_2$	$-OCH_3$	446	

The compounds of formula X_9



wherein R^7, R^8 and R^9 are as defined in Table 9, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.

TABLE 9

Example	R^7	R^8	R^9	*ES+	*ES-
173	-O-CH_2CH_2-1-piperidyl	$-OCH_3$	-H	470.3	468.3
174	-O-(1-methyl-azacycloheptyl-4-yl)	-H	-H	440	
175	-O-(1-methyl-azacyclopent-2-yl)	-H	-H	440	438

176	-O-CH_2CH_2-CH_2-1-imidazolyl	-OCH_3	-H	467	465
177	-OCH_3	-OCH_3	-OCH_3		
178	-O-CH_2CH_2-1-(1,2,4-triazolyl)	-H	-H	424	422
179	-O-CH_2CH_2-1-piperidyl	-H	-H		
180	-O-CH_2CH_2-OH	-OCH_3	-H		
181	-O-CH_2CH_2-4-morpholino	-H	-H	442	440
182	-O-$CH_2CH_2CH_2$-1-imidazolyl	-H	-H		

The compounds of formula X_{10}



wherein R^1, R^7 and R^9 are as defined in Table 10, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.

TABLE 10

EX	R^1	R^7	R^9	*ES+	*ES-
183	-CH_2CH_2-OH	-OCH_3	-OCH_3	411	409
184	-SO_2NH_2	-O-CH_2CH_2-1-imidazolyl	-H	496.3	494.3

The compounds of formula X_{11}



wherein R^8 is –OCH_3 (Example 185) or –OH (Example 186), may be prepared by following the procedure of Example 1 but using the appropriate starting materials.

The compounds of formula X_{12}



wherein R^0, R^1, R^7, R^8 and R^9 are as defined in Table 12, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.

TABLE 12

Example	R^0	R^1	R^7	R^8	R^9
187	-H	-H	-H	$-SO_2NH_2$	-H
188	-H	-H	-H	-H	$-CH_3$
189	-H	-H	-H	$-CH_3$	-H
190	-H	-F	$-OCH_3$	$-OCH_3$	$-OCH_3$
191	-H	-H	-H	$-CH_3$	$-CH_3$
192	-H	-H	$-CH_3$	-H	$-CH_3$
193	-H	-H	$-OCH_3$	$-CH_3$	-H
194	-H	-H	-H	-H	$-N(CH_3)_2$
195	-H	-H	$-OCH(CH_3)_2$	-H	-H
196	-H	-H	-H	$-OCH(CH_3)_2$	-H
197	-H	-H	$-CH(CH_3)_2$	-H	-H
198	-H	-H	-H	-CH=N-NH-	
199	-H	-H	$-OCH_3$	$-CH_3$	$-OCH_3$
200	$-OCH_3$	-H	$-OCH_3$	$-OCH_3$	$-OCH_3$
201	-H	-H	-H	-H	-H
202	$-CH_3$	-Cl	$-OCH_3$	$-OCH_3$	$-OCH_3$
203	-H	-H	-H	-H	$-CF_3$
204	-Cl	$-CH_3$	$-OCH_3$	$-OCH_3$	$-OCH_3$
205	-H	-H	-H	-NH-CH=N-	
206	-H	-H	-H	$-N(-CH_2CH_2CH_2$-4-morpholino)-CH=CH-	
207	-H	-H	$-CH_2CH_2-$ CH_2-		-H

The compounds of formula X_{13}



wherein R^1, R^2, R^3 and R^5 are as defined in Table 13, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.

TABLE 13

Example	R^1	R^2	R^3	R^5	*ES+	*ES-
208	-H	-H	$-SO_2NHCH_3$	$-CF_3$	514.0	
209	-H	-H	$-SO_2NHC_3H_7$	-Br		
210	-H	-H	$-SO_2NH-CH_2CH-$ cyclopropyl	-Br		
211	-H	-H	$-SO_2NHCH_3$	$-CH_3$		
212	-H	-H	$-SO_2N(CH_3)_2$	-Br		
213	-H	-H	$-SO_2NHCH_3$	-Cl		
214	-H	-H	$-SO_2NHCH_3$	-I		
215	-H	-H	$-SO_2NHCH_3$	-Br		
216	$-CH_3$	$-OCH_3$	$-SO_2NH_2$	-H	476	474
217	-H	piperidino	$-SO_2NH_2$	-H	515.5	513.4
218	-H	morpholino	$-SO_2NH_2$	-H	517.4	515.4
219	-H	$-C_2H_5$	$-SO_2NH_2$	-H		
220	-H	$-CH_3$	$-SO_2NH_2$	-Cl		
221	-H	$-CH_3$	$-SO_2NHCH_3$	-H	460.4	
222	-H	phenyl	$-SO_2NH_2$	-H	508.2	506.3

The compounds of formula X_{14}



wherein R^2, R^3, R^5, R^7, R^8 and R^9 are as defined in Table 14, may be prepared by following the procedure of Example 1 but using the appropriate starting materials.

TABLE 14

Ex	R^2	R^3	R^5	R^7	R^8	R^9	*ES+	*ES-
223	$-OCH_3$	$-SO_2NH_2$	-H	-H	-CH=N-N(CH_3)-			424
224	$-OCH_3$	$-SO_2NH_2$	-H	$-O-CH_2CH_2-OCH_3$	$-OCH_3$	-H	476.2	474.3

225	$-OCH(CH_3)_2$	$-SO_2NH_2$	-H	$-O-CH_2CH_2-$ piperidino	$-OCH_3$	-H	551.2	555.3
226	$-OCH_3$	$-SO_2NH_2$	-H	$-O-CH_2CH_2-$(4-methyl-piperazin-1-yl)	-H	-H	514.3	512.3
227	$-OCH_3$	$-SO_2NH_2$	-H	-morpholino	$-OCH_3$	-H	487.1	485.2
228	$-CH_3$	$-SO_2NH_2$	-H	$-O-CH_2CH_2CH_2-$ piperidino	$-OCH_3$	-H	527.3	
229	$-CH_3$	$-SO_2NH_2$	-H	$-O-CH_2CH_2CH_2-$1-pyrrolidinyl	$-OCH_3$	-H	513.2	511.3
230	$-O-CH_2CH_2-OCH_3$	$-SO_2NH_2$	-H	-H	$-CH=N-N(CH_3)-$		539	537
231	-(4-methyl-piperazin-1-yl)	$-SO_2NH_2$	-H	$-OCH_3$	$-OCH_3$	$-OCH_3$	530.4	528.4
232	$-OCH_3$	$-SO_2NH_2$	-H	$-O-CH_2CH_2-OH$	$-OCH_3$	-H	462.2	460.3
233	$-OCH_3$	$-SO_2NH_2$	-Br	$-O-CH_2CH_2-OCH_3$	$-OCH_3$	-H		
234	$-CH_3$	$-SO_2NH_2$	-H	$-O-CH_2CH_2-$(4-methyl-piperazin-1-yl)	$-OCH_3$	-H	528.2	526.3
235	$-CH_3$	$-SO_2NH_2$	-H	$-O-CH_2CH_2-N(CH_3)_2$	-H	-H	443.2	441.3
236	-H	$-SO_2NH_2$	-H	$-O-CH_2CH_2-$1-pyrrolidinyl	$-OCH_3$	-H	485.2	483.3
237	$-CH_3$	$-SO_2NH_2$	-H	-H	$-N(CH_3)-N=CH-$		410	
238	$-CH_3$	$-SO_2NH_2$	-H	$-CH_3$	$-OCH_3$	OCH_3		
239	$-CH_3$	$-SO_2NH_2$	-Br	$-O-CH_2CH_2-OCH_3$	$-OCH_3$	-H	538/540	
240	$-OCH_3$	$-SO_2NH_2$	-H	$-OCH_3$	-H	-H	402.2	400.2
241	-H	$-SO_2NH_2$	-H	-H	$-CO-NH-CH_2CH_2-OCH_3$	-H		

ES+ means electrospray MS positive mode ; ES- means electrospray MS negative mode; and EL means electron impact MS.

The compounds of formula I and their pharmaceutically acceptable salts, exhibit valuable pharmacological properties when tested in in vitro assays, and are therefore useful as pharmaceuticals. They are effective especially as protein tyrosine kinase inhibitors; they

exhibit, for example, powerful inhibition of the tyrosine kinase activity of anaplastic lymphoma kinase (ALK) and the fusion protein of NPM-ALK . This protein tyrosine kinase results from a gene fusion of nucleophosmin (NPM) and the anaplastic lymphoma kinase (ALK), rendering the protein tyrosine kinase activity of ALK ligand-independent. NPM-ALK plays a key role in signal transmission in a number of hematopoetic and other human cells leading to hematological and neoplastic diseases, for example in anaplastic large-cell lymphoma (ALCL) and non-Hodgkin's lymphomas (NHL), specifically in ALK+ NHL or Alkomas, in inflammatory myofibroblastic tumors (IMT) and neuroblastomas. (Duyster J et al. 2001 Oncogene 20, 5623-5637). In addition to NPM-ALK other gene fusions have been identified in human hematological and neoplastic diseases; mainly TPM3-ALK (a fusion of nonmuscle tropomyosin with ALK).

The ALK inhibitory activity and inhibitory activity against ALK-containing gene fusions of the compounds described herein make them useful pharmaceutical agents for the treatment of proliferative diseases. A proliferative disease is mainly a tumor disease (or cancer) (and/or any metastases). The inventive compounds are particularly useful for treating a tumor which is a breast cancer, genitourinary cancer, lung cancer, gastrointestinal cancer, epidermoid cancer, melanoma, ovarian cancer, pancreas cancer, neuroblastoma, head and/or neck cancer or bladder cancer, or in a broader sense renal, brain or gastric cancer; in particular (i) a breast tumor; an epidermoid tumor, such as an epidermoid head and/or neck tumor or a mouth tumor; a lung tumor, for example a small cell or non-small cell lung tumor; a gastrointestinal tumor, for example, a colorectal tumor; or a genitourinary tumor, for example, a prostate tumor (especially a hormone-refractory prostate tumor); or (ii) a proliferative disease that is refractory to the treatment with other chemotherapeutics; or (iii) a tumor that is refractory to treatment with other chemotherapeutics due to multidrug resistance.

In a broader sense of the invention, a proliferative disease may furthermore be a hyperproliferative condition such as leukemias, hyperplasias, fibrosis (especially pulmonary, but also other types of fibrosis, such as renal fibrosis), angiogenesis, psoriasis, atherosclerosis and smooth muscle proliferation in the blood vessels, such as stenosis or restenosis following angioplasty. Proliferative diseases treated according to the present method include tumors of blood and lymphatic system (e.g. Hodgkin's disease, Non-Hodgkin's

lymphoma, Burkitt's lymphoma, AIDS-related lymphomas, malignant immunoproliferative diseases, multiple myeloma and malignant plasma cell neoplasms, lymphoid leukemia, acute or chronic myeloid leukemia, acute or chronic lymphocytic leukemia, monocytic leukemia, other leukemias of specified cell type, leukemia of unspecified cell type, other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissues, for example diffuse large cell lymphoma, T-cell lymphoma or cutaneous T-cell lymphoma). Myeloid cancer includes e.g. acute or chronic myeloid leukaemia.

Where a tumor, a tumor disease, a carcinoma or a cancer are mentioned, also metastasis in the original organ or tissue and/or in any other location are implied alternatively or in addition, whatever the location of the tumor and/or metastasis.

The compound is selectively toxic or more toxic to rapidly propiferating cells than to normal cells, particularly in human cancer cells, e.g., cancerous tumors, the compound has significant antiproliferative effects and promotes differentiation, e.g., cell cycle arrest and apoptosis.

The compounds of the present invention may be administered alone or in combination with other anticancer agents, such as compounds that inhibit tumor angiogenesis, for example, the protease inhibitors, epidermal growth factor receptor kinase inhibitors, vascular endothelial growth factor receptor kinase inhibitors and the like; cytotoxic drugs, such as antimetabolites, like purine and pyrimidine analog antimetabolites; antimitotic agents like microtubule stabilizing drugs and antimitotic alkaloids; platinum coordination complexes; anti-tumor antibiotics; alkylating agents, such as nitrogen mustards and nitrosoureas; endocrine agents, such as adrenocorticosteroids, androgens, anti-androgens, estrogens, anti-estrogens, aromatase inhibitors, gonadotropin-releasing hormone agonists and somatostatin analogues and compounds that target an enzyme or receptor that is overexpressed and/or otherwise involved a specific metabolic pathway that is upregulated in the tumor cell, for example ATP and GTP phosphodiesterase inhibitors, protein kinase inhibitors, such as serine, threonine and tyrosine kinase inhibitors, for example, Abelson protein tryosine kinase and the various growth factors, their receptors and kinase inhibitors therefore, such as, epidermal growth factor receptor kinase inhibitors, vascular endothelial growth factor receptor kinase inhibitors, fibroblast growth factor inhibitors, insulin-like growth factor receptor inhibitors and platelet-derived growth factor receptor kinase inhibitors and the

like; methionine aminopeptidase inhibitors, proteasome inhibitors, and cyclooxygenase inhibitors, for example, cyclooxygenase-1 or –2 inhibitors. Such antiproliferative agents further include, aromatase inhibitors, antiestrogens, topoisomerase I inhibitors, topoisomerase II inhibitors, microtubule active agents, alkylating agents, histone deacetylase inhibitors, farnesyl transferase inhibitors, COX-2 inhibitors, MMP inhibitors, mTOR inhibitors, antineoplastic antimetabolites, platin compounds, compounds decreasing the protein kinase activity and further anti-angiogenic compounds, gonadorelin agonists, anti-androgens, bengamides, bisphosphonates, antiproliferative antibodies and temozolomide (TEMODAL®).

The term "aromatase inhibitors" as used herein relates to compounds which inhibit the estrogen production, i.e. the conversion of the substrates androstenedione and testosterone to estrone and estradiol, respectively. The term includes, but is not limited to steroids, especially exemestane and formestane and, in particular, non-steroids, especially aminoglutethimide, vorozole, fadrozole, anastrozole and, very especially, letrozole. A combination of the invention comprising an antineoplastic agent which is an aromatase inhibitor may particularly be useful for the treatment of hormone receptor positive breast tumors.

The term "antiestrogens" as used herein relates to compounds which antagonize the effect of estrogens at the estrogen receptor level. The term includes, but is not limited to tamoxifen, fulvestrant, raloxifene and raloxifene hydrochloride.

The term "topoisomerase I inhibitors" as used herein includes, but is not limited to topotecan, irinotecan, 9-nitrocamptothecin and the macromolecular camptothecin conjugate PNU-166148 (compound A1 in WO99/17804).

The term "topoisomerase II inhibitors" as used herein includes, but is not limited to the antracyclines doxorubicin (including liposomal formulation, e.g. CAELYX™), epirubicin, idarubicin and nemorubicin, the anthraquinones mitoxantrone and losoxantrone, and the podophillotoxines etoposide and teniposide.

The term "microtubule active agents" relates to microtubule stabilizing and microtubule destabilizing agents including, but not limited to the taxanes paclitaxel and docetaxel, the vinca alkaloids, e.g., vinblastine, especially vinblastine sulfate, vincristine especially

vincristine sulfate, and vinorelbine, discodermolide and epothilones, such as epothilone B and D.

The term "alkylating agents" as used herein includes, but is not limited to cyclophosphamide, ifosfamide and melphalan.

The term "histone deacetylase inhibitors" relates to compounds which inhibit the histone deacetylase and which possess antiproliferative activity.

The term "farnesyl transferase inhibitors" relates to compounds which inhibit the farnesyl transferase and which possess antiproliferative activity.

The term "COX-2 inhibitors" relates to compounds which inhibit the cyclooxygenase type 2 enyzme (COX-2) and which possess antiproliferative activity such as celecoxib (Celebrex®), rofecoxib (Vioxx®) and lumiracoxib (COX189).

The term "MMP inhibitors" relates to compounds which inhibit the matrix metalloproteinase (MMP) and which possess antiproliferative activity.

The term "antineoplastic antimetabolites" includes, but is not limited to 5-fluorouracil, tegafur, capecitabine, cladribine, cytarabine, fludarabine phosphate, fluorouridine, gemcitabine, 6-mercaptopurine, hydroxyurea, methotrexate, edatrexate and salts of such compounds, and furthermore ZD 1694 (RALTITREXED™), LY231514 (ALIMTA™), LY264618 (LOMOTREXOL™) and OGT719.

The term "platin compounds" as used herein includes, but is not limited to carboplatin, cis-platin and oxaliplatin.

The term "compounds decreasing the protein kinase activity and further anti-angiogenic compounds" as used herein includes, but is not limited to compounds which decrease the activity of e.g. the Vascular Endothelial Growth Factor (VEGF), the Epidermal Growth Factor (EGF), c-Src, protein kinase C, Platelet-derived Growth Factor (PDGF), Bcr-Abl tyrosine kinase, c-kit, Flt-3 and Insulin-like Growth Factor I Receptor (IGF-IR) and Cyclin-dependent kinases (CDKs), and anti-angiogenic compounds having another mechanism of action than decreasing the protein kinase activity.

Compounds which decrease the activity of VEGF are especially compounds which inhibit the VEGF receptor, especially the tyrosine kinase activity of the VEGF receptor, and compounds binding to VEGF, and are in particular those compounds, proteins and monoclonal antibodies generically and specifically disclosed in WO 98/35958 (describing compounds of formula I), WO 00/09495, WO 00/27820, WO 00/59509, WO 98/11223, WO 00/27819, WO 01/55114, WO 01/58899 and EP 0 769 947; those as described by M. Prewett et al in Cancer Research 59 (1999) 5209-5218, by F. Yuan et al in Proc. Natl. Acad. Sci. USA, vol. 93, pp. 14765-14770, December 1996, by Z. Zhu et al in Cancer Res. 58, 1998, 3209-3214, and by J. Mordenti et al in Toxicologic Pathology, vol. 27, no. 1, pp 14-21, 1999; in WO 00/37502 and WO 94/10202; Angiostatin™, described by M. S. O'Reilly et al, Cell 79, 1994, 315-328; and Endostatin™, described by M. S. O'Reilly et al, Cell 88, 1997, 277-285;
compounds which decrease the activity of EGF are especially compounds which inhibit the EGF receptor, especially the tyrosine kinase activity of the EGF receptor, and compounds binding to EGF, and are in particular those compounds generically and specifically disclosed in WO 97/02266 (describing compounds of formula IV), EP 0 564 409, WO 99/03854, EP 0520722, EP 0 566 226, EP 0 787 722, EP 0 837 063, WO 98/10767, WO 97/30034, WO 97/49688, WO 97/38983 and, especially, WO 96/33980;
compounds which decrease the activity of c-Src include, but are not limited to, compounds inhibiting the c-Src protein tyrosine kinase activity as defined below and to SH2 interaction inhibitors such as those disclosed in WO97/07131 and WO97/08193;
compounds inhibiting the c-Src protein tyrosine kinase activity include, but are not limited to, compounds belonging to the structure classes of pyrrolopyrimidines, especially pyrrolo[2,3-d]pyrimidines, purines, pyrazopyrimidines, especially pyrazo[3,4-d]pyrimidines, pyrazopyrimidines, especially pyrazo[3,4-d]pyrimidines and pyridopyrimidines, especially pyrido[2,3-d]pyrimidines. Preferably, the term relates to those compounds disclosed in WO 96/10028, WO 97/28161, WO97/32879 and WO97/49706;
compounds which decreases the activity of the protein kinase C are especially those staurosporine derivatives disclosed in EP 0 296 110 (pharmaceutical preparation described in WO 00/48571) which compounds are protein kinase C inhibitors;
further specific compounds that decrease protein kinase activity and which may also be used in combination with the compounds of the present invention are Imatinib (Gleevec®/Glivec®), PKC412, Iressa™ (ZD1839), PKI166, PTK787, ZD6474, GW2016, CHIR-200131, CEP-7055/CEP-5214, CP-547632 and KRN-633;

anti-angiogenic compounds having another mechanism of action than decreasing the protein kinase activity include, but are not limited to e.g. thalidomide (THALOMID), celecoxib (Celebrex), SU5416 and ZD6126.

The term "gonadorelin agonist" as used herein includes, but is not limited to abarelix, goserelin and goserelin acetate. Goserelin is disclosed in US 4,100,274.

The term "anti-androgens" as used herein includes, but is not limited to bicalutamide (CASODEX™), which can be formulated, e.g. as disclosed in US 4,636,505.

The term "bengamides" relates to bengamides and derivatives thereof having aniproliferative properties.

The term "bisphosphonates" as used herein includes, but is not limited to etridonic acid, clodronic acid, tiludronic acid, pamidronic acid, alendronic acid, ibandronic acid, risedronic acid and zoledronic acid.

The term "antiproliferative antibodies" as used herein includes, but is not limited to trastuzumab (Herceptin™), Trastuzumab-DM1, erlotinib (Tarceva™), bevacizumab (Avastin™), rituximab (Rituxan®), PRO64553 (anti-CD40) and 2C4 Antibody.

The structure of the active agents identified by code nos., generic or trade names may be taken from the actual edition of the standard compendium "The Merck Index" or from databases, e.g. Patents International (e.g. IMS World Publications).
The compositions of the invention may be administered by any conventional route, in particular parenterally, for example in the form of injectable solutions or suspensions, enterally, e.g. orally, for example in the form of tablets or capsules, topically, e.g. in the form of lotions, gels, ointments or creams, or in a nasal or a suppository form. Pharmaceutical compositions comprising an agent of the invention in association with at least one pharmaceutical acceptable carrier or diluent may be manufactured in conventional manner by mixing with a pharmaceutically acceptable carrier or diluent. Unit dosage forms for oral administration contain, for example, from about 0.1 mg to about 500 mg of active substance. Topical administration is e.g. to the skin. A further form of topical administration is to the eye.

The compounds of formula I may be administered in free form or in pharmaceutically acceptable salt form, e.g. as indicated above. Such salts may be prepared in conventional manner and exhibit the same order of activity as the free compounds.

The inhibition of ALK tyrosine kinase activity is measured using known methods, for example using the recombinant kinase domain of the ALK in analogy to the VEGF-R kinase assay described in J. Wood et al. Cancer Res. 60, 2178-2189 (2000). The table below reports the IC50 values for several compounds of the present invention. Each compound is tested twice, once each with two different preparations of ALK.

compound	IC50 µM
Ex. 48	0.048
Ex. 48	0.083
Ex. 58	0.046
Ex. 58	0.090
Ex. 56	0.18
Ex. 56	0.086

The compounds of formula I potently inhibit the growth of human NPM-ALK overexpressing murine BaF3 cells. The expression of NPM-ALK is achieved by transfecting the BaF3 cell line with an expression vector pCIneo™ (Promega Corp., Madison WI, USA) coding for NPM-ALK and subsequent selection of G418 resistant cells. Non-transfected BaF3 cells depend on IL-3 for cell survival. In contrast NPM-ALK expressing BaF3 cells (named BaF3-NPM-ALK) can proliferate in the absence of IL-3 because they obtain proliferative signal through NPM-ALK kinase. Putative inhibitors of the NPM-ALK kinase therefore abolish the growth signal and result in antiproliferative activity. The antiproliferative activity of putative inhibitors of the NPM-ALK kinase can however be overcome by addition of IL-3 which provides growth signals through an NPM-ALK independent mechanism. [for an analogous cell system using FLT3 kinase see E Weisberg et al. Cancer Cell; 1, 433-443 (2002). The inhibitory activity of the compounds of formula I is determined, briefly, as follows: BaF3-NPM-ALK cells (15 000/microtitre plate well) are transferred to 96-well microtitre plates. The test compounds [dissolved in dimethyl sulfoxide (DMSO)] are added in a series of concentrations (dilution series) in such a manner that the final concentration of DMSO is not greater than 1 % (v/v). After the addition, the plates are incubated for two days during which the control cultures without test compound are able to undergo two cell-division cycles. The growth of the BaF3-NPM-ALK cells is measured by means of Yopro™ staining (T Idziorek et al. J.

Immunol. Methods; 185:249-58 [1995]) : 25 µl of lysis buffer consisting of 20 mM sodium citrate, pH 4.0, 26.8 mM sodium chloride, 0.4 % NP40, 20 mM EDTA and 20 mM was added to each well. Cell lysis was completed within 60 min at room temperature and total amount of Yopro bound to DNA was determined by measurement using the Cytofluor II 96-well reader (PerSeptive Biosystems) with the following settings: Excitation (nm) 485/20 and Emission (nm) 530/25.

IC_{50} values are determined by a computer-aided system using the formula:

$$IC_{50} = [(ABS_{test} - ABS_{start})/(ABS_{control} - ABS_{start})] \times 100.$$

The IC_{50} value in those experiments is given as that concentration of the test compound in question that results in a cell count that is 50 % lower than that obtained using the control without inhibitor. The compounds of formula I exhibit inhibitory activity with an IC_{50} in the range from approximately 0.01 to 1 µM.

The antiproliferative action of the compounds of formula I can also be determined in the human KARPAS-299 lympoma cell line (described in WG Dirks et al. Int. J. Cancer 100, 49-56 (2002) using the same methodology described above for the BaF3-NPM-ALK cell line. The compounds of formula I exhibit inhibitory activity with an IC_{50} in the range from approximately 0.01 to 1 µM.

The following compounds are tested in the cellular assays in the BaF3 cell lines and the KARPAS-299 cell line as described above:

	BaF3	BaF3	KARPAS-299
	NPM-ALK with IL3	NPM-ALK without IL3	
	IC50 (µM)	IC50 (µM)	IC50 (µM)
Ex. 56	2.7	0.41	0.15
Ex. 58	2.6	0.56	0.33
Ex. 48	1.4	0.55	0.27

Claims:

1. A method of treating or preventing a condition susceptible to treatment with an ALK inhibiting agent which comprises inhibiting ALK or a gene fusion thereof with a compound of formula I



(I)

wherein

X is $=CR^0-$ or $=N-$;

each of R^0, R^1, R^2, R^3 and R^4 independently is hydrogen; hydroxy; C_1-C_8alkyl; C_2-C_8alkenyl; C_3-C_8cycloalkyl; C_3-C_8cycloalkyl-C_1-C_8alkyl; hydroxyC_1-C_8alkyl; C_1-C_8alkoxyC_1-C_8alkyl; hydroxyC_1-C_8alkoxyC_1-C_8alkyl; arylC_1-C_8alkyl which optionally may be substituted on the ring by hydroxy, C_1-C_8alkoxy, carboxy or C_1-C_8alkoxycarbonyl;

or R^3 and R^4 form together with the nitrogen and carbon atoms to which they are attached a 5 to 10 membered heterocyclic ring and comprising additionally 1, 2 or 3 heteroatoms selected from N, O and S;

or each of R^1, R^2 and R^3, independently, is halogen; halo-C_1-C_8alkyl; C_1-C_8alkoxy; halo-C_1-C_8alkoxy; hydroxyC_1-C_8alkoxy; C_1-C_8alkoxyC_1-C_8alkoxy; aryl; arylC_1-C_8alkoxy; heteroaryl; heteroaryl-C_1-C_4alkyl; 5 to 10 membered heterocyclic ring; nitro; carboxy; C_2-C_8alkoxycarbonyl; C_2-C_8alkylcarbonyl; -N(C_1-C_8alkyl)C(O) C_1-C_8alkyl; -N(R^{10})R^{11}; -CON(R^{10})R^{11}; -SO_2N(R^{10})R^{11}; or -C_1-C_4-alkylene-SO_2N(R^{10})R^{11}; wherein each of R^{10} and R^{11} independently is hydrogen; hydroxy; C_1-C_8alkyl; C_2-C_8alkenyl; C_3-C_8cycloalkyl; C_3-C_8cycloalkyl-C_1-C_8alkyl; C_1-C_8alkoxyC_1-C_8alkyl; hydroxyC_1-C_8alkoxyC_1-C_8alkyl; hydroxyC_1-C_8alkyl; (C_1-C_8alkyl)-carbonyl; arylC_1-C_8alkyl which optionally may be substituted on the ring by hydroxy, C_1-C_8alkoxy, carboxy or C_2-C_8alkoxycarbonyl; or 5 to 10 membered heterocyclic ring;

or R^1 and R^2 form together with the C-atoms to which they are attached aryl or a 5 to 10 membered heteroaryl residue comprising one or two heteroatoms selected from N, O and S; or

each of R^5 and R^6 independently is hydrogen; halogen; cyano; C_1-C_8alkyl; halo-C_1-C_8alkyl; C_2-C_8alkenyl; C_2-C_8alkynyl; C_3-C_8cycloalkyl; C_3-C_8cycloalkylC_1-C_8alkyl; C_5-C_{10}arylC_1-C_8alkyl;

each of R^7, R^8 and R^9 is independently hydrogen; hydroxy; C_1-C_8alkyl; C_2-C_8alkenyl; halo-C_1-C_8alkyl; C_1-C_8alkoxy; C_3-C_8cycloalkyl; C_3-C_8cycloalkylC_1-C_8alkyl; arylC_1-C_8alkyl; -Y-R^{12} wherein Y is a direct bond or O and R^{12} is a substituted or unsubstituted 5, 6 or 7 membered heterocyclic ring comprising 1, 2 or 3 heteroatoms selected from N, O and S; carboxy; (C_1-C_8alkoxy)-carbonyl; -N(C_{1-8}alkyl)-CO-$NR^{10}R^{11}$; -$CONR^{10}R^{11}$; -N(R^{10})(R^{11}); -$SO_2N(R^{10})R^{11}$; R^7 and R^8 or R^8 and R^9, respectively form together with the carbon atoms to which they are attached, a 5 or 6 membered heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S; or a 5 or 6 membered carbocyclic ring.

in free form or salt form.

2. A method according to claim 1 wherein at most one of R^1, R^2 or R^3 is -$CON(R^{10})R^{11}$; or -$SO_2N(R^{10})R^{11}$.

3. A method of claim 1 wherein the condition is a proliferative disease.

4. A method of claim 1 wherein a gene fusion containing ALK is inhibited.

5. Use of a compound of formula I



(I)

wherein

X is =CR^0- or =N-;

each of R^0, R^1, R^2, R^3 and R^4 independently is hydrogen; hydroxy; C_1-C_8alkyl; C_2-C_8alkenyl; C_3-C_8cycloalkyl; C_3-C_8cycloalkyl-C_1-C_8alkyl; hydroxyC_1-C_8alkyl; C_1-C_8alkoxyC_1-C_8alkyl; hydroxyC_1-C_8alkoxyC_1-C_8alkyl; arylC_1-C_8alkyl which optionally may be substituted on the ring by hydroxy, C_1-C_8alkoxy, carboxy or C_1-C_8alkoxycarbonyl;

or R^3 and R^4 form together with the nitrogen and carbon atoms to which they are attached a 5 to 10 membered heterocyclic ring and comprising additionally 1, 2 or 3 heteroatoms selected from N, O and S;

or each of R^1, R^2 and R^3, independently, is halogen; halo-C_1-C_8alkyl; C_1-C_8alkoxy; halo-C_1-C_8alkoxy; hydroxyC_1-C_8alkoxy; C_1-C_8alkoxyC_1-C_8alkoxy; aryl; arylC_1-C_8alkoxy; heteroaryl; heteroaryl-C_1-C_4alkyl; 5 to 10 membered heterocyclic ring; nitro; carboxy; C_2-C_8alkoxycarbonyl; C_2-C_8alkylcarbonyl; -N(C_1-C_8alkyl)C(O) C_1-C_8alkyl; -N(R^{10})R^{11};

$-CON(R^{10})R^{11}$; $-SO_2N(R^{10})R^{11}$; or $-C_1$-C_4-alkylene-$SO_2N(R^{10})R^{11}$; wherein each of R^{10} and R^{11} independently is hydrogen; hydroxy; C_1-C_8alkyl; C_2-C_8alkenyl; C_3-C_8cycloalkyl; C_3-C_8cycloalkyl-C_1-C_8alkyl; C_1-C_8alkoxyC_1-C_8alkyl; hydroxyC_1-C_8alkoxyC_1-C_8alkyl; hydroxyC_1-C_8alkyl; (C_1-C_8alkyl)-carbonyl; arylC_1-C_8alkyl which optionally may be substituted on the ring by hydroxy, C_1-C_8alkoxy, carboxy or C_2-C_8alkoxycarbonyl; or 5 to 10 membered heterocyclic ring;

or R^1 and R^2 form together with the C-atoms to which they are attached aryl or a 5 to 10 membered heteroaryl residue comprising one or two heteroatoms selected from N, O and S; or

each of R^5 and R^6 independently is hydrogen; halogen; cyano; C_1-C_8alkyl; halo-C_1-C_8alkyl; C_2-C_8alkenyl; C_2-C_8alkynyl; C_3-C_8cycloalkyl; C_3-C_8cycloalkylC_1-C_8alkyl; C_5-C_{10}arylC_1-C_8alkyl;

each of R^7, R^8 and R^9 is independently hydrogen; hydroxy; C_1-C_8alkyl; C_2-C_8alkenyl; halo-C_1-C_8alkyl; C_1-C_8alkoxy; C_3-C_8cycloalkyl; C_3-C_8cycloalkylC_1-C_8alkyl; arylC_1-C_8alkyl; -Y-R^{12} wherein Y is a direct bond or O and R^{12} is a substituted or unsubstituted 5, 6 or 7 membered heterocyclic ring comprising 1, 2 or 3 heteroatoms selected from N, O and S; carboxy; (C_1-C_8alkoxy)-carbonyl; $-N(C_{1\text{-}8}alkyl)-CO-NR^{10}R^{11}$; $-CONR^{10}R^{11}$; $-N(R^{10})(R^{11})$; $-SO_2N(R^{10})R^{11}$; R^7 and R^8 or R^8 and R^9, respectively form together with the carbon atoms to which they are attached, a 5 or 6 membered heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S; or a 5 or 6 membered carbocyclic ring.

in free form or salt form;

for the preparation of a medicament for the treatment of a hematological and neoplastic disease.

6. A use according to claim 5 wherein at most one of R^1, R^2 or R^3 is $-CON(R^{10})R^{11}$; or $-SO_2N(R^{10})R^{11}$.

3. A use according to claim 5 wherein the condition is a proliferative disease.

4. A use according to claim 5 wherein a gene fusion containing ALK is inhibited.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/010466

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D239/48 C07D405/12 C07D403/12 C07D401/12 C07D401/14
A61K31/506 A61K35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, CHEM ABS Data, BEILSTEIN Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 03/066601 A (SMITHKLINE BEECHAM CORP ; VEAL JAMES MARVIN (US); CHEUNG MUI (US); NAI) 14 August 2003 (2003-08-14) page 2, line 31 - page 3, line 24 page 26, line 30 - page 30, line 27 page 57 - page 77; examples 1-45	1-8
X	WO 01/64656 A (PEARSON STUART ERIC ; PEASE ELIZABETH JANET (GB); ASTRAZENECA UK LTD () 7 September 2001 (2001-09-07) page 22, line 27 page 27, line 19 - line 23 page 31 - page 43; examples 1-41	1-8

-/--

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier document but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
1 December 2004	23/12/2004

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Büttner, U

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/010466

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97/19065 A (CELLTECH THERAPEUTICS LTD ; DAVIS PETER DAVID (GB); MOFFAT DAVID FESTU) 29 May 1997 (1997-05-29) page 14, line 30 - line 35 page 51 - page 64; compounds 90-125	1-8
X	WO 03/074515 A (CHAMBERLAIN STANLEY DAWES ; SMITHKLINE BEECHAM CORP (US); CHEUNG MUI () 12 September 2003 (2003-09-12) page 125 - page 220; examples 1-239 page 47, line 15 - line 18	1-8
X	WO 03/030909 A1 (BAYER CORPORATION, USA) 17 April 2003 (2003-04-17) page 2, line 32 - page 3, line 2 examples 12,72-153	1-8
X	WO 03/018021 A1 (AMGEN INC., USA) 6 March 2003 (2003-03-06) page 186, line 15 - page 189, line 8; examples 66-306	1-8
P,X	WO 03/078404 A1 (NOVARTIS A.-G., SWITZ.; NOVARTIS PHARMA G.M.B.H.) 25 September 2003 (2003-09-25) page 8 - page 21; claims 1,4-10; compounds 1-241	1-8
P,X	WO 2004/056786 A (KATH JOHN CHARLES ; LUZZIO MICHAEL JOSEPH (US); PFIZER PROD INC (US)) 8 July 2004 (2004-07-08) page 24, line 8 - line 35 page 28, line 25 - line 32 page 49 - page 50; examples 1,2 page 81; example 58	1-8
P,X	WO 2004/074244 A (SMITHKLINE BEECHAM CORP ; NEEB MICHAEL J (US); DAVIS-WARD RONDA (US);) 2 September 2004 (2004-09-02) page 96; example 39	1-8
E	WO 2004/080980 A (NOVARTIS PHARMA GMBH ; NOVARTIS AG (CH); GARCIA-ECHEVERRIA CARLOS (CH)) 23 September 2004 (2004-09-23) the whole document	1-8

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2004/010466

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 1-4 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. [ ] Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP2004/010466

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 03066601 A	14-08-2003	CA 2476281 A1	14-08-2003
		EP 1472233 A1	03-11-2004
		WO 03066601 A1	14-08-2003
WO 0164656 A	07-09-2001	AU 3397901 A	12-09-2001
		BR 0108879 A	29-04-2003
		CA 2398887 A1	07-09-2001
		CN 1416423 T	07-05-2003
		EP 1278735 A1	29-01-2003
		WO 0164656 A1	07-09-2001
		JP 2003525279 T	26-08-2003
		MX PA02007581 A	13-12-2002
		NO 20024126 A	29-08-2002
		NZ 520502 A	28-05-2004
		US 2003181474 A1	25-09-2003
		ZA 200206192 A	26-11-2003
WO 9719065 A	29-05-1997	AU 7631496 A	11-06-1997
		DE 69627179 D1	08-05-2003
		DE 69627179 T2	29-01-2004
		EP 0862560 A1	09-09-1998
		ES 2195020 T3	01-12-2003
		WO 9719065 A1	29-05-1997
		US 6235746 B1	22-05-2001
		US 5958935 A	28-09-1999
WO 03074515 A	12-09-2003	WO 03074515 A1	12-09-2003
WO 03030909 A1	17-04-2003	NONE	
WO 03018021 A1	06-03-2003	US 2004063705 A1	01-04-2004
		CA 2457838 A1	06-03-2003
		EP 1427421 A1	16-06-2004
WO 03078404 A1	25-09-2003	NONE	
WO 2004056786 A	08-07-2004	WO 2004056807 A1	08-07-2004
		WO 2004056786 A2	08-07-2004
		NL 1025067 A1	22-06-2004
		NL 1025071 A1	22-06-2004
		US 2004220177 A1	04-11-2004
WO 2004074244 A	02-09-2004	WO 2004074244 A2	02-09-2004
WO 2004080980 A	23-09-2004	WO 2004080980 A1	23-09-2004